You just read:

Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis

News provided by

Respivant Sciences

May 20, 2019, 08:00 ET